The EU’s debut Joint Clinical Assessment was run on a drug that exposes every trap waiting for orphan developers in 2028.
The convention opens with the FDA short of leaders, while Europe's new drug-vetting system stumbles on its first attempt.
A cluster of recent deals put AI discovery platforms at the center. The terms, optioned and hedged, are more cautious than the conviction suggests.
Obesity just went from the 30th most-studied disease to the 2nd in three years, and almost the entire bet is riding on a single class of drugs.
Sponsors keep misreading red flags for green, yet the traits FDA actually falls for are predictable enough to plan a whole program around.
GSK spends $10.6bn to outrun a patent cliff while the Pentagon quietly reprices the supply chain underneath everyone. Two different bets on the same question: what is access actually worth.
Cutting headcount to survive the next milestone creates exposures distinct from those of growth, and most boards underestimate them.
Two of pharma's most crowded fields, and no agreement on whether the answer is to crowd in further or step away.
The UK's new "notifiable trial" route can shave weeks off your timeline, but only if you sequence your jurisdictions like a chess player rather than a tourist.
The needle-shy are the prize now, and four companies showed up to ADA with a pill and a percentage.
ASCO ended a week ago. The filing and the deal structure that deserve a closer look.
